| INTRODUCTION
Inflammatory bowel diseases (IBD; Crohn's disease [CD] , ulcerative colitis [UC]) are complex immunologically mediated diseases that affect an estimated 1.6 million individuals in the USA. [1] [2] [3] [4] The availability of biological therapies, namely tumour necrosis factor-a antagonists (anti-TNF) (infliximab, adalimumab, certolizumab pegol, golimumab) and anti-integrin therapies (vedolizumab, natalizumab), have significantly increased our ability to achieve clinical and endoscopic remission. 2, 3, 5 However, loss of response to these therapies remains an important clinical challenge, in part due to immunogenicity leading to heightened clearance and reduced drug levels. [6] [7] [8] [9] [10] [11] [12] This has led to interest in combining biological therapy with a conventional immunomodulator to both achieve synergy and reduce immunogenicity.
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This therapeutic paradigm of combination therapy received significant momentum with the publication of landmark clinical trials in CD and UC that demonstrated greater rates of clinical and endoscopic remission with a combination of infliximab and azathioprine when compared to either agent alone. 13, 14 However, not all randomised trials have demonstrated similar benefit 15, 16 and observational studies have also demonstrated conflicting results with some suggesting benefit 17 while others found no incremental value. 18 In addition to conflicting data about efficacy, widespread use of combination immunosuppression in all IBD patients is also limited by concerns about safety including risk of opportunistic infections and therapy-related malignancy. [19] [20] [21] [22] In addition, the heterogeneity in clinical course of both CD and UC suggests that many patients may experience a prolonged period of mild disease and not universally require aggressive-therapy up front. [23] [24] [25] [26] Thus, there is a need to stratify patients who may be most likely to benefit from combination therapy.
Limitations of prior studies on the topic have been small sample size, determination of treatment outcomes retrospectively, and lack of information on hard endpoints such as hospitalisations or surgeries that contribute significantly to morbidity and healthcare costs in patients with IBD. Consequently, we performed this analysis in a prospective multicenter cohort of patients with CD and UC to determine the benefit of combination therapy with an immunomodulator over anti-TNF monotherapy.
2 | ME TH ODS
| Study population
The data source for our study was a prospective, multicenter cohort of patients with CD and UC, the Sinai Helmsley Alliance for Research Excellence (SHARE) cohort. Details of this cohort have been described in detail in previous publications. 27 In brief, the cohort included patients with a diagnosis of CD, UC or IBD- 
| Statistical analysis
All statistical analysis was performed using Stata 14.0 (StataCorp, College Station, TX, USA). Continuous variables were summarised using means and standard deviation while categorical variables were described using proportions and compared using the t test. Univariate logistic regression was performed against the composite outcome for each disease-related covariate and demographic variable.
Then, multivariable logistic regression models were constructed to calculate odds ratios (OR) and 95% confidence intervals (CI) incorporating variables significant in the univariate analysis with a P<.05 or those that had been previously described in the literature to predict the outcomes of interest. Pre-specified stratified analysis was performed by disease duration and phenotype in both CD and UC. A two-sided P≤.05 in a multivariable model indicated independent statistical significance. As allocation to monotherapy or combination therapy groups was non-random, a sensitivity analysis was performed incorporating an adjustment for a propensity score in the multivariable model. The propensity score determined the likelihood of a given patient receiving combination therapy given baseline characteristics. Such adjustment minimises the potential bias introduced by nonrandom treatment group allocation. 30 Institutional Review
Board approval for this study was obtained from each center.
3 | RESULTS
| Study population
Our study included a total of 871 IBD patients (707 CD, 164 UC) among whom 492 (56%) were on anti-TNF monotherapy and 379 (44%) were on combination therapy with an immunomodulator ANANTHAKRISHNAN ET AL.
| 163 (Table 1) . Patients on combination therapy were similar to those on monotherapy in demographic characteristics, age at diagnosis and disease duration. Nearly four-fifths of patients in both groups had CD. There was a trend towards a larger proportion with stricturing or penetrating disease behaviour in the combination therapy group, and more frequent perianal involvement without differences in prior surgery or disease location. There was no difference in extent of UC between the two groups. The most common anti-TNFs were infliximab and adalimumab in both groups and nearly two-thirds of patients in both groups were on their first biological agent. Threequarters of patients on combination therapy were on thiopurines (azathioprine or mercaptopurine).
| Crohn's disease
On follow-up at 1 year, 276 (32%) patients had an event comprising the composite outcome (22% hospitalisation, 10% surgery, 9% new biological, 6% new fistula or abscess and 2% new steroid prescription). 
| Ulcerative colitis

| DISCUSSION
The paradigm of using combination immunomodulator-biological therapy received substantial support with the publication of two landmark clinical trials. 13, 14 The SONIC study in immunomodulatorna€ ıve CD demonstrated that higher rates of clinical remission and mucosal healing were achieved with a combination of infliximab and azathioprine when compared to either therapy alone. 13 The UC SUCCESS trial demonstrated a similar phenomenon in UC. 14 However, limitations of these two trials include restriction to patients who had not previously been on immunomodulators and limited statistical power to determine potential adverse effects of dual immunosuppressive therapy. Thus, whether a benefit of combination therapy extends to real-world clinical practice of patients, many of whom had previously failed anti-TNF or immunomodulator monotherapy, is not well established and the subgroups of patients most likely to benefit have been poorly defined.
Using data from a prospective, multicenter cohort, we demonstrate that the benefit of combination therapy in CD is most striking in those with complicated stricturing or penetrating CD, particularly within 5 years of diagnosis. The latter observation is consistent with prior studies demonstrating that the greatest benefit with treatment may be early in the disease course. 31 In the PRECISE 2 trial of certolizumab pegol, nearly 90% of patients with disease duration less than 1 year were able to maintain response compared to only 57% of those with disease duration of 5 years or greater. 31 Further support for the benefit of intervening early on in the disease is indirectly derived from the higher rates of response observed in trials of anti-TNF therapy in paediatric patients compared to adults with | 165 more established disease. [32] [33] [34] The hypothesis behind the lower rates of response with long duration of disease is the development of irreversible fibrostenotic complications and permanent bowel damage that are not be amenable to modification by medical therapy.
The literature on the potential benefit of combination therapy has been inconsistent with heterogeneity in study design and conflicting observations. As in our study, many other observational cohorts and randomised controlled trials have concluded that combination therapy did not modify outcomes in an unselected group of patients with IBD, many of whom had failed immunomodulator therapy previously. Two recent clinical trials, the COMMIT study examining a combination of infliximab and methotrexate, 15 and the DIAMOND study of adalimumab and azathioprine 16 failed to show an improvement in clinical outcomes with combination therapy though more detailed analysis suggested higher trough levels could be obtained than with infliximab monotherapy. 15 While some retrospective cohorts have noted that combination therapy prolonged persistence on therapy, 17 others have failed to find a benefit. In an analysis of Medicare data, Osterman et al. did not find a reduction in IBD-related hospitalisations or surgery at 1 year with combination therapy when compared to monotherapy. 18 As well, post-hoc analyses of clinical trials have shown either no clinical benefit over monotherapy or only a modest improvement in efficacy with combination therapy, particularly for infliximab. 9, 35 It is well recognised that both CD and UC are heterogeneous in their natural history. 2, 3, [23] [24] [25] [26] 36, 37 While many patients present with aggressive disease at presentation or go on to develop penetrating or fibrotic complications early or require surgery, many others may have a mild course, never requiring immunosuppressive therapy or surgery. One factor driving the need to stratify patients who may derive the greatest benefit from combination therapy is concerns about safety of dual immunosuppressive therapy. In a pooled analysis of data from clinical trials of adalimumab in CD, combined immunosuppressive therapy was associated with an increased risk of opportunistic infections, particularly herpes zoster. 19, 35 The same data also described a threefold increase in risk of both skin and systemic malignancy with combination therapy, 20 a finding confirming prior observations of numerically higher risk of non-Hodgkin's lymphoma with combination therapy. 22,38 While we were not able to examine the risks associated with combination therapy in our population, our findings suggest that the greatest benefit may be obtained in those with complicated CD. Further studies are also needed to determine if the development of such complicated phenotype can be prevented by early institution of combination therapy.
Importantly, we also show that this benefit exists not only with infliximab, but also with other formulations of anti-TNF agents in contrast to prior studies in established disease have suggested benefit primarily among infliximab users.
We acknowledge several limitations of our study. First, we did not have information on duration of anti-TNF or immunomodulator use prior to enrolment in our cohort, and thus are not able to examine if prior response to immunomodulators influences benefit when used in combination. There is conflicting data on whether prior lack of response to thiopurines determines benefit with combination therapy. Some studies have suggested that the benefit of combination therapy is greater in the thiopurine naive setting 39 while others have demonstrated that prior non-response to thiopurines does not influence their benefit when used in combination with a biological. 40 Jones et al., in a pooled analysis of randomised trials, demonstrated concomitant immunomodulator use to be associated with increased rates of clinical remission and response with infliximab therapy even in a population where the majority had previously failed thiopurine therapy. 9 We also lacked data on duration of anti-TNF use before enrolment in our cohort; however, it has been demonstrated that the annual rate of loss of response remains the same on continued anti-TNF use, and thus we do not expect this to influence to our findings. 7, 8 We did not have serial C-reactive protein, faecal calprotectin, or endoscopic severity scores to quantify the benefit of combination therapy on those parameters in our cohort. That being said, hospitalisations and surgeries remain key endpoints in IBD, accounting for a significant fraction of the morbidity and healthcare costs associated with these diseases. We also acknowledge limited statistical power, particularly in UC where fewer patients were on anti-TNF therapy. Furthermore, we did not have sufficient participants on anti-integrin or other biological therapy to examine if the benefit potentially extended to such treatment mechanisms.
In conclusion, we demonstrate that a combination of immunomodulator-anti TNF therapy was associated with decreased rates of hospitalisation and surgery in complicated Crohn's disease, particularly within 5 years of diagnosis. Despite concern about potential risks of dual immunosuppression, given the risks of progression of disease with inadequate control of inflammation, physicians should consider starting combination therapy to prevent irreversible bowel damage and ensure optimal outcomes.
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